This executive summary will explore the benchmark practices for rapid progression from first–in–human to large–scale commercial manufacture for microdosing API. Xcelodose®–based systems are an industry standard for rapid and accurate microdosing and an integral part of accelerated pathways to first–in–human studies. Utilization of the Xcelodose® technology can increase speed to clinic and quickly assess new compounds while remaining cost–conscious. Upon successful clinical studies, scale up to large–scale manufacture has previously been a limitation. Read the executive summary to learn more.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center